Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma

Scarpa, Marco; Noaro, Giulia; Saadeh, Luca Maria; Cavallin, Francesco; Cagol, Matteo; Alfieri, Rita; Plebani, Mario; Castoro, Carlo

doi:10.1007/s00268-014-2835-1

Cited by 23 publications

(19 citation statements)

References 31 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent report, Scarpa et al demonstrated the usefulness of preoperative serum CEA and CA19-9 levels for detecting occult advanced esophageal adenocarcinoma [16]. In their study, the incidence of CA19-9 positivity was 12.3%, which was similar to that found in our study.…”

Section: Discussionsupporting

confidence: 90%

Carbohydrate antigen 19‐9 is a useful prognostic marker in esophagogastric junction adenocarcinoma

et al. 2015

View full text Add to dashboard Cite

The incidence rate of esophagogastric junction (EGJ) adenocarcinoma has been rapidly increasing worldwide. Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are major serum tumor markers in gastrointestinal cancers. However, the role of these markers in EGJ adenocarcinoma has not been thoroughly investigated. A total of 211 patients with EGJ adenocarcinoma who underwent surgery or endoscopic submucosal dissection at two academic institutions, Kumamoto University Hospital or Kyushu University Hospital between January 1996 and March 2014, were eligible for this study. Serum CEA and CA19-9 were examined within 1 month before resection. The cut-off values for CEA and CA19-9 were set at 5.0 ng/mL and 37 U/mL, respectively. The clinicopathological features and prognostic roles of the markers were examined using univariate and multivariate analyses. The positive ratios for preoperative CEA (>5.0 ng/mL) and CA19-9 (>37 U/mL) were 20.3% and 12.9%, respectively. The positive ratio of CEA and CA19-9 was significantly higher in patients with tumors invading muscular or deeper layers (P = 0.002 and <0.001, respectively). Cox proportional hazards model revealed that CA19-9 positivity, but not CEA positivity, was an independent prognostic factor in patients with EGJ adenocarcinoma for cancer-specific survival (multivariate hazard ratio [HR] = 3.89, 95% confidence interval [CI] 1.41–10.33; P = 0.010) and overall survival (multivariate HR = 2.43, 95% CI 1.03–5.35; P = 0.043). Preoperative serum CA19-9 is a useful prognostic marker in patients with EGJ adenocarcinoma.

show abstract

Section: Discussionsupporting

confidence: 90%

Carbohydrate antigen 19‐9 is a useful prognostic marker in esophagogastric junction adenocarcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…For example, Brockmann and colleagues discovered that CYFRA21-1 serum levels correlated with EC tumor burden [3]. Scarpa et al discovered that preoperative CEA and CA19.19 levels could be used as biomarkers of occult advanced EAC [4]. Gion et al found that serum levels of CEA and TPA correlated with the extent of ESCC [5].…”

Section: Introductionmentioning

confidence: 99%

LC–MS/MS determination of d-mannose in human serum as a potential cancer biomarker

White

Liang

et al. 2017

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Several metabolites in human serum have been identified as potential cancer biomarkers for early detection. This study focuses on the LC–MS/MS method development and validation of D-mannose in human serum. Surrogate blank serum, coupled with stable isotope D-mannose-13C6, as internal standard, was used for generating standard curves ranging from 1 to 50 μg/mL. Separation was achieved by an Agilent 1200 series HPLC equipped with a SUPELCOGELTM Pb, 6% Crosslinked column with HPLC water as a mobile phase at flow rate of 0.5 mL/min at 80 °C. Mass detection was performed under negative ionization electrospray. Inter- and intra-day accuracy and precision were <2%. The extraction recovery and matrix effect were 104.1%–105.5% and 97.0%–100.0%, respectively. This method was successfully applied for the quantification of D-mannose in the serum samples of 320 esophageal cancer patients and 323 healthy volunteers. We report a simple, specific and reproducible LC–MS/MS method for the quantification of D-mannose in human serum as a potential cancer biomarker.

show abstract

“…In line with the current literature, risk factors for tumor recurrence such as an increased ASA-score, elevated levels of CA 19-9, or an advanced tumor stage have been described [11,[25][26][27][28][29]. Whether postoperative complications like anastomotic leakage affect the incidence of tumor relapse is discussed controversially [12,13].…”

Section: Discussionmentioning

confidence: 89%

Prognostic Impact of Lymph Node Localization in Node-Positive Esophageal Cancer

Eichelmann¹,

Palmes²,

Kneifel³

et al. 2020

COR

View full text Add to dashboard Cite

Background: Recurrent disease remains a major problem for esophageal cancer. This study was designed to evaluate the impact of localization of lymph node metastasis for tumor recurrence following curative esophageal resection. Methods: 273 patients undergoing esophagectomy for esophageal cancer between 2005 and 2014 at the Department of General, Visceral and Transplant Surgery, University Hospital of Münster were included. Tumor characteristics, treatment details, postoperative course and patients' outcome, including time point and localization of recurrent disease, were analyzed retrospectively. The median follow-up was 46.3 months. Results: Median overall and disease-free survivals were 22.7 and 13 months, respectively. Tumor characteristics including presence and number of lymph node metastasis, and localization of lymph node metastases, paraesophageal, perigastric and intra-abdominal, had significant impact on both tumor recurrence (p<0.001, p=0.003, and p=0.001, respectively) and disease-free survival (p<0.001, p=0.001, and p<0.001, respectively). Univariate and multivariate analysis confirmed tumor stage, lymph node metastasis, G-, L- and V-category, and neoadjuvant treatment as independent predictors of tumor recurrence. Conclusion: The tumor stage and response to neoadjuvant treatment remain the most important prognostic factors. In addition, localization and the number of resected lymph node metastasis can provide important additional information.

show abstract

Esophageal Cancer Management: Preoperative CA19.9 and CEA Serum Levels May Identify Occult Advanced Adenocarcinoma

Abstract: Preoperative CEA and CA19.9 serum levels should be taken in consideration when evaluating patients candidate to esophagectomy for esophageal cancer to prevent inappropriate laparotomy or thoracotomy. If any doubt arises minimally invasive exploration is warranted.

Cited by 23 publications

References 31 publications

Carbohydrate antigen 19‐9 is a useful prognostic marker in esophagogastric junction adenocarcinoma

Carbohydrate antigen 19‐9 is a useful prognostic marker in esophagogastric junction adenocarcinoma

LC–MS/MS determination of d-mannose in human serum as a potential cancer biomarker

Prognostic Impact of Lymph Node Localization in Node-Positive Esophageal Cancer

Contact Info

Product

Resources

About